发明公开
EP4397317A2 COMBINATION THERAPY OF LASMIDITAN AND A CGRP ANTAGONIST FOR USE IN THE TREATMENT OF MIGRAINE
审中-实审
基本信息:
- 专利标题： COMBINATION THERAPY OF LASMIDITAN AND A CGRP ANTAGONIST FOR USE IN THE TREATMENT OF MIGRAINE
- 申请号：EP24170976.5 申请日：2018-08-30
- 公开(公告)号：EP4397317A2 公开(公告)日：2024-07-10
- 发明人： AURORA, Sheena , JOHNSON, Kirk Willis , KREGE, John Henry
- 申请人： Eli Lilly and Company
- 申请人地址： US Indianapolis, IN 46285 Lilly Corporate Center
- 专利权人： Eli Lilly and Company
- 当前专利权人： Eli Lilly and Company
- 当前专利权人地址： US Indianapolis, IN 46285 Lilly Corporate Center
- 代理机构： Faggiani, Davide
- 优先权： US 1762554726P 2017.09.06
- 分案原申请号： 18766557.5 2018.08.30
- 主分类号： A61K39/395
- IPC分类号： A61K39/395
摘要：
The present invention relates to combinations of lasmiditan and a calcitonin gene-related peptide (CGRP) antagonist such as rimegepant, ubrogepant, olcegepant, and MK-8031 and to methods of using the combinations for treatment of migraine, particularly migraine inadequately controlled by lasmiditan or a CGRP antagonist therapy alone, and more particularly, to treat therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment regimens.
公开/授权文献:
IPC结构图谱:
| A | 人类生活必需 |
| --A61 | 医学或兽医学；卫生学 |
| ----A61K | 医用、牙科用或梳妆用的配制品 |
| ------A61K39/00 | 含有抗原或抗体的医药配制品 |
| --------A61K39/395 | .抗体；免疫球蛋白；免疫血清，例如抗淋巴细胞血清 |